-+ 0.00%
-+ 0.00%
-+ 0.00%

Charles River Laboratories International Partners With Magellan Stem Cells For Development, Clinical Advancement Of Stem Cell-Based Therapies, Regenerative Medicine Solutions

Benzinga·10/13/2026 12:04:27
Listen to the news

Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s specialized expertise in biologics quality control, current Good Manufacturing Practice (cGMP) viral and release testing, and extensive development support services. By integrating Charles River's comprehensive testing and development solutions with Magellan’s advances in cell therapy development, manufacturing and clinical application, the collaboration aims to drive innovation and create shared value.